MEDIAIPLUS Unveils Innovative Clinical Trial Chatbot 'MeA': Personalized Clinical Trial Information for Patients and Researchers

Image: https://www.pangyotechnovalley.org/storage/ck/2025/01/nZ5PgHyf5rcL0VyBAhKk.jpeg

As CES 2025 concluded successfully, global attention focused on cutting-edge technologies from innovative companies. South Korea's Pangyo Techno Valley once again demonstrated its presence on the international stage, with startups specializing in AI, smart healthcare, and eco-friendly technology attracting visitors and investors.

Pangyo's innovation ecosystem, built through government and private sector collaboration, showcased remarkable achievements at CES. This report highlights Pangyo-based companies' unique technologies and growing global market competitiveness, positioning the region as a hub for future innovation.

MEDIAIPLUS Unveils 'MeA' at CES 2025: AI-Powered Clinical Trial Chatbot for Patients and Researchers

MEDIAIPLUS (CEO JiHee Jung) introduced its AI-powered clinical trial chatbot, 'MeA,' at CES 2025, held in Las Vegas from January 7 to 10. Designed to enhance accessibility to clinical trial information, MeA enables patients to search and enroll in ongoing clinical trials through an interactive chatbot interface.

Founded in January 2019, MEDIAIPLUS operates 'FiCRO,' a data-driven platform that matches clients with optimized Clinical Research Organizations (CROs), and 'MediC,' a subscription service offering real-time access to clinical trial data, patents, and academic resources across multiple countries. With over 700,000 clinical trial datasets, 'MediC' is a valuable tool for researchers and pharmaceutical companies designing clinical trials for drug and medical device approvals.

MeA, showcased at CES 2025, enhances MediC's functionality by providing patients direct access to its vast database via a chatbot. By simply entering details such as age, gender, condition, and location, patients can quickly receive a curated list of ongoing clinical trials and relevant information.

The chatbot's responsive design ensures accessibility by allowing seamless use across web and mobile devices. Additionally, MeA supports multiple languages, including English, Korean, and Japanese, broadening access to clinical trial information for global patients.

Video: https://www.youtube.com/embed/dbBi8mZGkZ0

Video Link: https://www.youtube.com/embed/dbBi8mZGkZ0

MeA also benefits researchers designing clinical trials. Traditionally, obtaining precise clinical trial data required extensive searches with complex filters. With MeA, researchers can input their desired criteria via chat, significantly reducing the time spent gathering information.

Inspired by her personal experiences of medical information disparity, JiHee Jung pursued a pharmaceutical career. While working as a Medical Science Liaison (MSL) and launching five new drugs, she realized the immense effort required to compile patents, clinical trial data, and regulatory guidelines. To address this challenge, she founded MEDIAIPLUS, bringing together experts from data science, pharmaceutical research, and engineering to develop a clinical data curation platform.

MEDIAIPLUS is expanding globally, targeting domestic companies seeking international certifications and foreign companies entering the Korean market. The company aims to lower barriers to clinical trials and expand its business model. Plans include launching additional services, such as researcher matching and predictive analytics for clinical trial approvals, further enhancing the clinical trial ecosystem.

Image: https://www.pangyotechnovalley.org/storage/ck/2025/01/FChQSIp3APAkXZOR4d2E.png

Pangyo Techno Valley is a global integrated R&D hub focused on IT, BT, CT, and NT, integrating Research (R), People (P), Information (I), and Trade (T). As Gyeonggi-do's representative innovation cluster, Pangyo Techno Valley was established to secure national new growth drivers such as technological innovation, human resource development, job creation, and enhancing international business competitiveness. As of 2023, 1,666 companies employ 78,751 people, and it has positioned itself as the most innovative hub in South Korea, with sales amounting to 167.7 trillion KRW (125.5 billion USD).

Furthermore, the Techno Valley Innovation Division of the Gyeonggi-do Business & Science Accelerator (GBSA) holds monthly events such as the Pangyo Evening Meet-Up, Pan-Pan Day, and the Pangyo Startup Investment Exchange "In-Best Pangyo" to maximize the value of Pangyo Techno Valley. They also support the Pangyo Overseas Promotion Program, which publicizes information about Pangyo's companies, products, and services to domestic and foreign investors and the media, thereby facilitating foreign investment.

Media Contact
Company Name: Gyeonggido Business and Science Accelerator (GBSA)
Contact Person: Seung Yeon Kim
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mediaiplus-unveils-innovative-clinical-trial-chatbot-mea-personalized-clinical-trial-information-for-patients-and-researchers]
Country: South Korea
Website: https://www.gbsa.or.kr/en/index.do



This release was published on openPR.